BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Summary by AI BETAClose X

BioNTech and OncoC4 announced that their selective Treg modulator, gotistobart, demonstrated a clinically meaningful overall survival benefit in patients with previously treated squamous non-small cell lung cancer. In the Phase 3 PRESERVE-003 trial, gotistobart showed a 54% reduction in the risk of death compared to standard chemotherapy, with a median overall survival not reached at nearly 15 months of follow-up, versus 10 months for chemotherapy. The drug also exhibited a manageable safety profile, with Grade ≥3 treatment-related adverse events occurring in 42.2% of patients on gotistobart compared to 48.8% on docetaxel. Gotistobart has received Fast Track Designation from the FDA for metastatic NSCLC patients progressing on prior anti-PD-(L)1 therapy.

Disclaimer*

UK 100

Latest directors dealings